Merial, Inc. v Intervet International B.V

Link copied
Case Copied 23 min read

FEDERAL COURT OF AUSTRALIA

Merial, Inc. v Intervet International B.V. [2016] FCA 1047

File number: VID 399 of 2015
Judge: MOSHINSKY J
Date of judgment: 30 August 2016
Catchwords: PRACTICE AND PROCEDURE – confidential documents – application for in-house counsel to have access to confidential documents – where documents to be relied on by party claiming confidentiality in evidence at trial – where in-house counsel is person giving instructions at trial – where in-house counsel not involved in competitive decision-making or product development
Legislation: Patents Act 1990 (Cth), ss 18(1)(b)(i), 18(b)(ii)
Cases cited:

AstraZeneca AB v Medis Pharma Pty Ltd [2014] FCA 549

Australian Competition and Consumer Commission v Air New Zealand Limited (No 3) [2012] FCA 1430

Gram Engineering Pty Limited v BlueScope Steel Pty Limited (No 2) [2016] FCA 452

Vringo Infrastructure Inc v ZTE (Australia) Pty Ltd (No 3) [2014] FCA 983

Date of hearing: 19, 30 August 2016
Registry: Victoria
Division: General Division
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Category: Catchwords
Number of paragraphs: 30
Counsel for the Appellant: Mr C Dimitriadis SC with Ms C Cunliffe
Solicitor for the Appellant: Ashurst Australia
Counsel for the Respondent: Mr CH Smith
Solicitor for the Appellant: Spruson & Ferguson Lawyers

ORDERS

VID 399 of 2015
BETWEEN:

MERIAL, INC.

Appellant

AND:

INTERVET INTERNATIONAL B.V.

Respondent

JUDGE:

MOSHINSKY J

DATE OF ORDER:

30 AUGUST 2016

THE COURTS NOTES THAT:

1.The appellant undertakes to be liable for any direct or indirect loss, damage, costs or expenses to or suffered by the respondent in the event of disclosure of the confidential information in the documents referred to in order 3 below by Dr Judy Jarecki-Black to any person other than a person subject to the confidentiality regime in place in respect of this proceeding.

2.The appellant has indicated that it provides the above undertaking on the basis stated by its counsel at the hearing today as recorded in the transcript.

UPON THE UNDERTAKING SET OUT ABOVE, THE COURT ORDERS THAT:

3.Subject to execution of a deed of undertaking in the form set out on page 36 of the affidavit of Grant Fisher dated 5 August 2016 in respect of the documents referred to below, and this being provided to the respondent’s solicitors, Dr Judy Jarecki-Black, Global Head, Intellectual Property of the appellant, shall be permitted to receive unredacted copies of the following documents:

(a)annexures KS-3, KS-4 and KS-5 to the affidavit of Dr Karin Stumm dated 24 June 2016; and

(b)the product development report dated 21 November 2002 provided by the respondent to the appellant on 15 August 2016 (and forming part of annexure GF-38 to the affidavit of Grant Fisher dated 16 August 2016).

4.Costs of the appellant’s third amended interlocutory application, to the extent not already dealt with, be reserved.

Note:    Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


REASONS FOR JUDGMENT

MOSHINSKY J:

Introduction

  1. The appellant (Merial) seeks an order that Dr Judy Jarecki-Black, who…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Merial, Inc. v Intervet International B.V and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2016] FCA 1047
Decision Date

CaseChat Overview and Summary

In the matter of Merial, Inc. v Intervet International B.V, the Federal Court of Australia was asked to decide whether Dr Judy Jarecki-Black, Global Head of Intellectual Property of Merial, could be granted access to certain confidential documents in the context of a patent dispute between Merial and Intervet. The documents in question included annexures to an affidavit and a product development report, which Intervet argued contained confidential information that could cause significant harm if disclosed to competitors. Merial argued that Dr Jarecki-Black, who would be giving instructions at trial, should have access to the unredacted documents.

The central legal issue was whether the confidential nature of the documents outweighed the need for Dr Jarecki-Black to have access to them for the purposes of instructing her legal team in the case. The court had to balance the protection of confidential information against the necessity of full disclosure for the administration of justice. Given that Dr Jarecki-Black was not involved in the competitive decision-making or product development processes that generated the confidential information, the court considered whether this distinction was sufficient to permit her access to the documents.

The court found that the need for Dr Jarecki-Black to have access to the unredacted documents for the purposes of giving instructions at trial was sufficiently compelling to justify allowing her access, subject to certain conditions. These included Merial providing an undertaking and Dr Jarecki-Black executing a deed of undertaking to ensure the confidentiality of the documents. The court concluded that the balance tipped in favour of permitting access, as the documents were crucial for the proper conduct of the trial and Dr Jarecki-Black's role did not involve the competitive processes that generated the confidential information.

Accordingly, the court ordered that Dr Jarecki-Black be permitted to receive unredacted copies of the specified documents, subject to the conditions mentioned. The costs of the application were reserved for later determination.

Orders

Orders of the court

3. Subject to execution of a deed of undertaking in the form set out on page 36 of the affidavit of Grant Fisher dated 5 August 2016 in respect of the documents referred to below, and this being provided to the respondent’s solicitors, Dr Judy Jarecki-Black, Global Head, Intellectual Property of the appellant, shall be permitted to receive unredacted copies of the following documents:

(a) annexures KS-3, KS-4 and KS-5 to the affidavit of Dr Karin Stumm dated 24 June 2016; and

(b) the product development report dated 21 November 2002 provided by the respondent to the appellant on 15 August 2016 (and forming part of annexure GF-38 to the affidavit of Grant Fisher dated 16 August 2016).

4. Costs of the appellant’s third amended interlocutory application, to the extent not already dealt with, be reserved.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

For the reasons that follow, subject to Merial giving an undertaking as discussed below, and subject to Dr Jarecki-Black executing a deed of undertaking (in the form that is in evidence) in respect of the relevant documents, I will order that Dr Jarecki-Black be permitted to receive unredacted copies of the relevant documents, namely:(a)annexures KS-3, KS-4 and KS-5 to the affidavit of Dr Stumm dated 24 June 2016; and(b)the 21 November 2002 Report.Background facts The proceeding is an appeal by Merial from a decision of the Commissioner of Patents (by her delegate) in relation to a patent application by Intervet in respect of an invention described as “compositions and process for delivering an additive”. By its third amended notice of appeal (intellectual property), Merial appeals from the whole of the decision of the Commissioner of Patents; specifically, the decisions of the Commissioner that the invention the subject of each of the claims of the application: (a) is novel within the meaning of s 18(1)(b)(i) of the Patents Act 1990 (Cth) (the Patents Act); and (b) involves an inventive step within the meaning of s 18(b)(ii) of the Act. Merial also opposes the grant of a patent on certain additional grounds, including lack of entitlement. In relation to its third amended interlocutory application, Merial relies on the affidavits of Grant Fisher (a partner of the solicitors acting for Merial) dated 5, 9, 16 and 19 August 2016. In opposition to the application, Intervet relies on the affidavits of John Afaras (a principal of the solicitors for Intervet) dated 10 and 19 August 2016. (I note that there are two affidavits of Mr Afaras dated 10 August 2016, but it is only the first of those affidavits that is relevant to this interlocutory application.) On the basis of those affidavits, the background facts for present purposes are as follows. The affidavits of both parties were prepared on the basis of information and belief. Three of the documents the subject of the present application are annexures KS-3, KS-4 and KS-5 to the affidavit of Dr Stumm dated 24 June 2016. Dr Stumm holds the position of Counsel, Intellectual Property Group Animal Health MSD – Office of General Counsel of Intervet. Dr Stumm’s affidavit has been filed by Intervet as part of its evidence for the hearing of the proceeding. In relation to annexure KS-3, Mr Afaras states in his affidavit dated 10 August 2016 that the document is a product development report that was generated for Intervet by a company known as Pharma Chemie; the report discloses a large number of placebo soft chew formulations; the report contains redacted (that is, confidential) information which consists of the results of evaluations of these formulations with respect to the variations of excipients used, the addition of alternative excipients and the sourcing of excipients from various sources, which evaluations were undertaken to assess the impact on processability and palatability of the formulations in dogs. Omitting words which are not relevant for present purposes, Mr Afaras states that:7.If such confidential information were disclosed … to a competitor of the Respondent that is also selling and developing soft chew formulations (such as the Appellant), the Respondent may suffer material prejudice. This is because there is a risk that knowledge obtained from the confidential formulation development history may inadvertently or innocently be used to the Respondent’s detriment in developing competing soft chew formulations, including drafting or advising on the Appellant’s patent applications in related technology areas, in competition with Intervet.8.In particular, the Respondent is in direct competition with the Appellant with respect to the formulation, production and manufacture of soft chew products for dogs. The primary selling point of these products is palatability in dogs and the formulations used in these products are subject to ongoing further development to optimise palatability. As a result, the redacted formulation development history contained in the report annexed as Annexure KS-3, including the evaluations of the excipients used in the formulations, is highly proprietary to the Respondent and disclosure to its competitors … may cause significant harm to the Respondent. Intervet would be assisted with its own product development work if it were to obtain access to equivalent research and development work that had been conducted by any of its competitors, including the Appellant.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.